OSE Immunotherapeutics SA OSE

€11.1 million cash position as of June 30, 2026; cash runway confirmed through December 2026The Company continues to engage actively with institutional investors in the United States and Europe to extend its cash runway beyond key upcoming value inflection pointsIn this context, publication of first half 2026 financial results is postponedEnrolment of Tedopi’s Phase 3 clinical trial ARTEMIA in lung cancer on track for completion by end of December 2026; planned futility analysis now estimated fo

Nantes, France, September 23, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the Combi-TED Phase 2 international clinical trial of Tedopi® in metastatic Non-Small Cell Lung Cancer sponsored by FoRT have been selected for an oral presentation at the 2026 Annual Meeting of the European Society for Me

Nantes, France, September 9, 2026 – 6pm CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the “Company”) welcomes the announcement by its licensee Veloxis Pharmaceuticals, Inc. that the first patient has been dosed in RENGEVITY-201, a Phase 2 clinical trial evaluating pegrizeprument (VEL-101) for the prevention of organ rejection in kidney transplant recipients. Pegrizeprument (also known as VEL-101) is a novel investigational immunomodulatory monoclonal monovalent antibody frag

NANTES, France, August 28, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company"), today announced that the Company will host a webcast with international experts in Inflammatory Bowel Diseases (IBD) to discuss its lead asset lusvertikimab on September 2, 2026, at noon ET (6pm CET). The discussion will focus on IL-7R biology, promising results from the CoTiKis Phase 2 clinical trial in Ulcerative Colitis, future development plans in Chronic Pouchitis and w

NANTES, France, July 8, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) – Under the liquidity contract entrusted by OSE Immunotherapeutics to Invest Securities, the following resources were available in the liquidity account as of June 30, 2026: 88,592 shares €250,888.59 in cash Over the period from 01/01/2026 to 30/06/2026: Number of executions on buy side: 899Number of executions on sell side: 918Traded volume on buy side: 208,453 shares for €859,440.90Traded vol

NANTES, France, June 24, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company"), today reported that all 42 resolutions submitted to a vote at the Combined General Shareholders’ Meeting held today were approved, with the exception of two of them (resolutions 7 and 14) being rejected as proposed by the Board of Directors. Full results are available on the Company’s website (www.ose-immuno.com), “Investors – General Shareholders’ Meetings” section. ABOUT OSE

NANTES, France, June 3, 2026 – 8:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company"), announced that it will hold its Annual General Meeting on June 24, 2026, at 10:00 am CET at Jones Day’s offices located 2 rue Saint Florentin, 75001 Paris, France. The General Meeting will also be webcast live for shareholders on the Company’s website (www.ose-immuno.com). The notice containing the agenda and draft resolutions was published in the French BALO on May 20, 2026. T

2025 Audited financial statements are consistent with Unaudited financial statements previously reported on April 30, 2026The IRIS Financing announced on May 28, 2026, was added as a subsequent eventConfirmed cash runway until the end of December 2026 after the IRIS Financing NANTES, France, June 3, 2026 – 8:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company"), today reported its full year 2025 audited consolidated financial results, as approved by the Board of D

First step of a global financing strategy, as the Company is actively engaging with institutional investors in the United States and in EuropeGross proceeds could amount to €19.3 million based on current share price1 over a 24-month periodCash runway to be extended to end of December 2026Subsequent filing of the 2025 Universal Registration Document now scheduled on June 3, 2026, to include this financing NANTES, France, May 28, 2026 – 9:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; M

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer Topline results to be presented by Alexandra Leary, MD, PhD, on May 30, 2026, at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in ChicagoOSE Immunotherapeutics to host a KOL webcast on June 10, 2026 Nantes, France, May 22, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to

OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi®1€22.7 and €17.0 million cash position as of December 31, 2025, and March 31, 2026, respectivelyUnchanged cash runway until early Q4 2026Filing of the 2025 Universal Registration Document is postponed to no later than May 28, 2026 NANTES, France, April 30, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the "Company"), today reported i

Nantes, France, April 27, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today welcomes the announcement by its partner Veloxis Pharmaceuticals, Inc. that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pegrizeprument (VEL‑101) for the prophylaxis of heart allograft rejection in patients receiving a heart transplant. This follows the recent ODD granted in January 2026 for prevention of organ rejection in patients receiving a li

Nantes, France, April 15, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that an abstract on a novel agonist monoclonal antibody targeting FPR2, a key receptor involved in the triggering resolution of inflammation, has been selected for an oral presentation at the 2026 Annual Meeting of the American Association of Immunolo